Fri Sep 20 12:16:16 UTC 2024: ## Medpace Stock Target Lowered by Robert W. Baird, Analysts Remain Mostly Bullish

**Cincinnati, OH -** Medpace Holdings, Inc (NASDAQ: MEDP) saw its price target reduced by Robert W. Baird on Friday, Sept 20th, 2024. The firm lowered its target price from $430.00 to $413.00, suggesting a potential upside of 11.87% from the company’s current price. Despite this, Robert W. Baird maintains an “outperform” rating on the stock.

This price target adjustment comes amidst a mixed bag of analyst opinions on Medpace. While StockNews.com downgraded the stock from “buy” to “hold”, other firms like William Blair and Guggenheim continue to express confidence in the company’s future, reaffirming their “outperform” and “buy” ratings respectively. Deutsche Bank Aktiengesellschaft, however, lowered its target price from $395.00 to $336.00 and set a “hold” rating.

Overall, the consensus rating for Medpace remains a “Moderate Buy” with a consensus price target of $420.88, according to MarketBeat.com. This indicates that a majority of analysts are still optimistic about the company’s prospects.

Medpace, a clinical research-based drug and medical device development services provider, recently announced strong Q2 earnings results on July 22nd. The company exceeded analyst expectations, reporting $2.75 EPS, a significant jump from the $1.93 EPS posted in the same quarter last year.

Institutional investors have been actively investing in Medpace. Vanguard Group Inc., TD Asset Management Inc, Renaissance Technologies LLC, Epoch Investment Partners Inc., and Clearbridge Investments LLC all increased their holdings in the stock during recent quarters. Currently, 77.98% of the stock is owned by institutional investors.

The company’s strong earnings, continued positive analyst sentiment, and robust institutional investor interest suggest a positive outlook for Medpace.

Read More